Arch Biopartners Inc V.ARCH

Alternate Symbol(s): ACHFF

Technology Scientific & Technical Instruments

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is LSALT Peptide. The Company is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The Company has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.

TSXV:ARCH - Post by User

Arch Biopartners Inc > This is great.

<< Previous

Bullboard Posts

Next >>

Comment by Antonius2on Nov 03, 2021 3:42pm

111 Views

Post# 34083674

RE:This is great.

Treatments that have been shown to work in phase II clinical trials must succeed in one more phase before they're approved for general use. Phase III clinical trials compare the safety and effectiveness of the new treatment against the current standard treatment. Since there is no current standard treatment for AKI - expect a sudden and very pronounced interest in the Arch drug Metablock if/when good results data is released in conjunction with 3rd party peer review.

<< Previous

Bullboard Posts

Next >>

Debt-free cannabis company set for next stage of growth